Marion Webb has been writing about medtech since 2017, specializing in covering buzzy segments such as robotic surgery, digital therapeutics and femtech with in-depth features and interviews with leading experts. Her role includes reporting live from industry events, moderating panel discussions and podcasts, tweeting breaking news and engaging KOLs to provide high-quality, business-critical content for Medtech Insight. Marion has been writing about health care issues for more than two decades. She was a long-time biotech reporter at the San Diego Business Journal, worked at Bloomberg News, and contributed to the Los Angeles County Medical Association’s Physician Magazine. Marion was born and raised in Germany, is fluent in German and conversational in Spanish. Off the job, she’s a competitive runner, avid cyclist and swimmer, and enjoys spending time with her domestic partner and her German Shorthair Pointer mix Cora.
Latest from Marion Webb
In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.
The medtech companies navigate tariffs through a mix of proactive manufacturing moves, financial planning and global supply chain adjustments. Medtech Insight combined comments from executives made during their first-quarter earning calls to get an industry pulse check on how the surge of tariffs im
This week, the FDA announced a new head of its device evaluation office; synthetic genomics firm Constructive Bio landed $58m in funding; and Natera got a permanent injuction against NeoGenomics Labs' RaDaR assay.
This week, Neuralink announced it received US FDA breakthrough device designation for a device to restore sight; medtechs Discure and DeepLook secured new funding; FDA pump recalls from B. Braun Medical and Fresenius Kabi; Axonics prevails in patent infringement lawsuit with Medtronic; Merit Medical buys Cook Medical for $210m.
This week, a medical group sued the FDA to block a lab-developed test rule; the FDA published guidance on device classifications; Defibtec issued a recall of its chest compression device and ICU Medical updated instructions for its infusion pump batteries; Maui Imaging raised a $4m DOD grant to put imaging tech into military-based trauma units.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.